Yes We Cann! create a better tomorrow

Comprehensive FDA Comment Package — Patient First Coalition & American Council of Cannabis Medicine (ACCM)

The comprehensive package of comment letters submitted to the FDA by the Patient First Coalition and the American Council of Cannabis Medicine (ACCM) brings together six important perspectives representing the medical cannabis community. These submissions provide a coordinated, patient-centered approach to federal medical cannabis policy, incorporating clinical expertise, scientific research, patient experiences, regulatory considerations, and industry knowledge.'

The six key perspectives represented in the package include:

1. Patient First Coalition – Patient-centered policy recommendations, patient protections, medical access, and a comprehensive national medical cannabis framework.
2. American Council of Cannabis Medicine (ACCM) – Medical cannabis standards, physician participation, insurance integration, national infrastructure, and responsible regulatory pathways.
3. Healthcare Professionals – Accepted medical use, physician involvement, clinical applications, and the importance of medically guided patient care.
4. Patients and Caregivers – Real-world patient experiences, access challenges, affordability, and continuity of care.
5. Scientific Researchers – Clinical evidence, whole-plant cannabis research, therapeutic applications, and expanded scientific investigation.
6. Licensed Cannabis Operators, Cultivators, and Agricultural Experts – Responsible cultivation, production standards, product quality, regulatory compliance, and reliable patient access.

Two central recommendations are emphasized throughout the submissions:

Federal Moratorium: Strong support for establishing a federal moratorium to protect patients, healthcare professionals, and existing state-licensed medical cannabis programs from unnecessary disruption while a comprehensive federal regulatory framework is developed.

National Medical Cannabis Commission: Strong support for creating a National Medical Cannabis Commission bringing together physicians, researchers, patients, regulators, and industry stakeholders to establish coordinated, science-based national medical cannabis policies and standards.

Together, the Patient First Coalition and ACCM submissions provide the FDA with a comprehensive, practical roadmap for advancing responsible medical cannabis policy. We encourage the FDA to utilize these letters as important reference materials, with particular consideration given to the proposed federal moratorium and establishment of a National Medical Cannabis Commission.

The docket and submissions are below.

For information call Lexie Henderson (202) 349-9650 ext. 800
 

The Patient First Coalition Medical Cannabis Committee supported by the American Council of Cannabis Medicine was built to help support the responsible transition of medical cannabis from Schedule I to Schedule III and to assist in shaping a modern, patient-centered national framework for implementation. Through the collaboration of healthcare leaders, patient advocates, insurers, compliance experts, technology innovators, pharmacy and dispensary professionals, and industry stakeholders, the Committee has developed recommendations designed to support public safety, medical integrity, responsible oversight, and long-term sustainability. We encourage policymakers, regulators, media, and stakeholders to review the expert public statements and testimony documents below, which were prepared to help guide thoughtful discussion and informed decision-making during this historic transition. 

For information call Lexie Henderson (202) 349-9650 ext. 800